Foghorn Therapeutics
Karin Hellsvik serves as Vice President of Corporate Affairs & Investor Relations and Chief of Staff to the CEO at Foghorn Therapeutics Inc. since April 2022, after a notable tenure at Biogen from May 2010 to April 2022 where roles included Executive Director and Head of Corporate Affairs for the Alzheimer's Business Unit. Hellsvik developed strategies for patient advocacy, external communications, and stakeholder engagement, playing a critical role in aligning patient voices with corporate strategy. Previously, experience in communications and healthcare was built at Navigator Communications and through various copywriting positions. Educational credentials include programs at INSEAD, Babson College, MGH Disparities Solutions Center, and Malmö University.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.